IA
ACOR

IFP Advisors’s Acorda Therapeutics ACOR Stock Holding History

IFP Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Hold
0
– – – 4178
2016
Q4 		– Sell
-1
Closed -$2.38K – 4182
2016
Q3 		$2K Buy
+1
New +$2.98K ﹤0.01% 3640
2016
Q1 		– Sell
-3
Closed -$14K – 3607
2015
Q4 		$14K Buy
+3
New +$13.1K ﹤0.01% 2405

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

IFP Advisors's ACOR Position: Q1 2017 in Review

IFP Advisors held its Acorda Therapeutics (ACOR) position steady in Q1 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4178.

IFP Advisors first reported a position in ACOR in Q4 2015 and has held it in 2 quarters since. The position peaked at $14K in Q4 2015. 178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • IFP Advisors held 0 shares of Acorda Therapeutics worth $0 as of Q1 2017.
  • IFP Advisors left its Acorda Therapeutics share count unchanged in Q1 2017.
  • Acorda Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q1 2017, its #4178 holding.
  • IFP Advisors first reported a position in Acorda Therapeutics in Q4 2015 and has held it in 2 quarters since.
  • IFP Advisors's Acorda Therapeutics position peaked at $14K in Q4 2015.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on IFP Advisors's 13F filing for Q1 2017, filed 26 Apr 2017.